



## **HTG Molecular to Present Corporate Overview at the Canaccord Genuity 39th Annual Growth Conference**

July 25, 2019

TUCSON, Ariz., July 25, 2019 (GLOBE NEWSWIRE) -- [HTG Molecular Diagnostics](#), Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski, President and CEO, will present a corporate overview at the Canaccord Genuity 39<sup>th</sup> Annual Growth Conference, being held in Boston, Massachusetts on August 7-8, 2019.

### ***HTG Molecular Presentation Details***

Date: Thursday, August 8  
Time: 2:30 pm Eastern Time

### **About HTG:**

HTG is focused on NGS-based molecular profiling. The company's proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG's customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

### **Contact:**

Ashley R. Robinson  
LifeSci Advisors, LLC  
Phone: (617) 535-7742  
Email: [arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)

Shaun McMeans  
Chief Financial Officer  
HTG Molecular Diagnostics  
Email: [smcmeans@htgmolecular.com](mailto:smcmeans@htgmolecular.com)



Source: HTG Molecular Diagnostics, Inc.